GSK plc (GSK)
| Market Cap | 98.21B +21.3% |
| Revenue (ttm) | 44.05B +5.0% |
| Net Income | 6.40B +40.8% |
| EPS | 3.13 +42.6% |
| Shares Out | 4.01B |
| PE Ratio | 15.35 |
| Forward PE | 9.98 |
| Dividend | $1.79 (3.62%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 2,701,322 |
| Open | 49.41 |
| Previous Close | 49.70 |
| Day's Range | 48.96 - 49.82 |
| 52-Week Range | 40.36 - 61.70 |
| Beta | 0.29 |
| Analysts | Hold |
| Price Target | 59.58 (+20.73%) |
| Earnings Date | Oct 28, 2026 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for GSK stock is "Hold." The 12-month stock price target is $59.58, which is an increase of 20.73% from the latest price.
News
AN2 announces extension of funding for tuberculosis research collaboration
AN2 Therapeutics (ANTX) announced that the Gates Foundation has awarded an extension of funding to support AN2 Therapeutics’ research activities under its ongoing tuberculosis research collaboration w...
GSK Bets on Long-Acting Biologics and AI to Reshape Respiratory Care
GSK NYSE: GSK is advancing a respiratory and immunology pipeline centered on longer-acting biologics, more targeted patient selection and combination approaches, according to Kaivan Khavandi, the comp...
GSK plc Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
The forum highlighted a robust pipeline in respiratory, immunology, and metabolic diseases, with a focus on ultra-long-acting biologics, novel mechanisms, and data-driven patient stratification. AI and global partnerships, especially in China, are accelerating development, while external innovation and M&A remain key to pipeline expansion.
GSK Targets £40B Sales as Oncology Push and £1.9B Savings Plan Take Shape
GSK NYSE: GSK Chief Financial Officer Julie Brown outlined the company's growth strategy, launch priorities and cost-savings plans during a discussion with Bank of America analyst Sachin Jain followin...
GSK plc Transcript: Bank of America Global Healthcare Conference
Management outlined a GBP 1.9 billion self-funded savings plan to accelerate growth, prioritize oncology, and support margin stability through 2030. Key launches like Excentia, BLENREP, and bepirovirsen are expected to drive future growth, while headwinds include TRELEGY IRA impacts and base effects on established products.
European drugmakers call for faster trials, more spending to compete with US, China
European drugmakers called for beefed-up government spending on medicines, faster trials and IP protections as they sounded warnings on Tuesday that the continent's pharmaceutical industry risks los...
ViiV Healthcare continues partnership with Prevention Access Campaign
ViiV Healthcare, the global specialist HIV company majority owned by GSK (GSK), with Shionogi as a shareholder, announced the continuation of its long-standing partnership with Prevention Access Campa...
GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer Pipeline
GSK NYSE: GSK is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and prostate cancer, with a combination of inte...
GSK plc Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The oncology portfolio has rapidly expanded through focused internal R&D and strategic acquisitions, with key assets like B7-H3, B7-H4, neladalkib, and zidesamtinib driving growth. Robust clinical data and disciplined strategy underpin confidence in meeting ambitious 2031 sales targets.
GSK enters agreement to acquire trispecific TCE from Chimagen
GSK (GSK) announced it has entered an agreement to acquire a trispecific T cell-engager, TCE, from Chimagen Biosciences, a privately held biotechnology company. GSK plans to develop and commercialize ...
GSK upgraded to Buy from Hold at Berenberg
Berenberg analyst Kerry Holford upgraded GSK (GSK) to Buy from Hold with a price target of 2,200 GBp, up from 2,000 GBp. The firm is “increasingly optimistic” about GSK’s growth…
GSK strikes up to $750 million deal for cancer-targeting drug
GSK said on Tuesday it had agreed a deal worth up to $750 million to buy a trispecific T cell-engager (TCE), a drug designed to help T-cells target cancer, from China-based biotechnology firm Chimag...
GSK presents results from phase I/II ARROS-1 trial evaluating Jideytro
GSK (GSK) announced positive results from the registrational phase I/II ARROS-1 trial evaluating Jideytro in patients with advanced or metastatic ROS1-positive non-small cell lung cancer, NSCLC, who h...
GSK licensor Hansoh announces ARTEMIS-008 phase III trial met primary endpoint
GSK (GSK) licensor Hansoh Pharmaceutical Group announced positive overall survival, OS, data from ARTEMIS-008, its phase III trial in China evaluating the B7-H3-targeted antibody-drug conjugate, ADC, ...
GSK Targets £1.9B Savings to Fuel Pipeline, Navigate HIV Patent Cliff
GSK NYSE: GSK is accelerating investment in research and development, expanding its late-stage pipeline and targeting cost savings to support product launches while maintaining profitability through u...
GSK to shut vaccine factory in Germany, putting 641 jobs at risk
GSK said on Friday it will be shutting down a vaccine factory in Dresden, Germany, which its website showed produces flu and hepatitis shots, in the summer of 2027.
GSK announces Japan’s MHLW approved prefilled syringe presentation of Shingrix
GSK (GSK) announced Japan’s Ministry of Health, Labour and Welfare, MHLW, has approved a prefilled syringe presentation of Shingrix for the prevention of shingles. The vaccine previously came as two…
GSK price target raised to 2,000 GBp from 1,860 GBp at HSBC
HSBC raised the firm’s price target on GSK (GSK) to 2,000 GBp from 1,860 GBp and keeps a Hold rating on the shares. The firm adjusted targets in the healthcare…
GSK plc Transcript: Bernstein’s 23rd Annual Pan-European Strategic Decisions Conference
Leadership is accelerating R&D and simplifying operations, driving GBP 2 billion in savings to fund a robust pipeline, including HIV long-acting injectables, oncology, and liver disease innovations. Commercial execution and specialty focus support margin stability through key patent expiries.
GSK initiated with a Sector Perform at RBC Capital
RBC Capital analyst Trung Huynh initiated coverage of GSK (GSK) with a Sector Perform rating and 1,975 GBp price target The shares are up 30% over the past year reflecting…
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Drugmakers are getting a boost from strong earnings and M&A. But they're also havens in a rocky market.
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
HUTCHMED NASDAQ: HCM said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The t...
Hutchmed, GSK enter HMPL-A830 commercialization agreement
Hutchmed (HCM) announced that its subsidiary, Hutchmed Limited, has entered into an exclusive development and license agreement with a subsidiary of GSK (GSK), granting the GSK subsidiary worldwide ri...
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug
GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay a unit of HUTCHMED (China) $110 million upfront for rights to an experimental drug for solid tumours, the Chinese drugmaker ...
GSK to advance mRNA flu vaccine to late-stage trial
GSK said on Tuesday it will advance its mRNA-based seasonal influenza vaccine candidate into a late-stage trial after mid-stage data showed it generated stronger immune responses than curr...